<DOC>
	<DOCNO>NCT00087438</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Stereotactic body radiation therapy may able deliver x-ray directly tumor cause less damage normal tissue . PURPOSE : This phase II trial study well stereotactic body radiation therapy work treat patient inoperable stage I stage II non-small cell lung cancer .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy Treating Patients With Inoperable Stage I Stage II Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether treatment stereotactic body radiotherapy result acceptable local control ( i.e. , ≥ 80 % ) patient medically inoperable stage I II non-small cell lung cancer . Secondary - Determine treatment-related toxicity patient treat therapy . - Determine disease-free survival , overall survival , patterns failure patient treat therapy . OUTLINE : This multicenter study . Patients receive 3 fraction stereotactic body radiotherapy 8-14 day absence disease progression unacceptable toxicity . Patients follow 6 12 week , every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 52 patient accrue study within 26 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) The following primary cancer subtypes eligible : Squamous cell carcinoma Adenocarcinoma Large cell carcinoma Bronchoalveolar cell carcinoma Nonsmall cell carcinoma otherwise specify Stage I II disease base 1 follow tumor node metastasis ( TNM ) stage criterion : T1 , N0 , M0 T2 ( ≤ 5 cm ) , N0 , M0 T3 ( ≤ 5 cm ) , N0 , M0 ( chest wall primary tumor ) No primary tumor Tstage within touch zone proximal bronchial tree* NOTE : *Defined volume 2 cm direction around proximal bronchial tree ( carina , right leave main bronchus , right leave upper lobe bronchus , intermedius bronchus , right middle lobe bronchus , lingular bronchus , right leave low lobe bronchus ) No primary T3 tumor involve central chest ( ≤ 2 cm toward carina invasion ) structure mediastinum Any hilar mediastinal lymph node &gt; 1 cm CT scan OR demonstrate suspicious uptake positronemission tomography scan must biopsied confirmed negative NSCLC The primary tumor must deem technically resectable reasonable possibility obtain gross total resection negative margin ( define potentially curative resection ( PCR ) ) Deemed medically inoperable base pulmonary function surgical resection NSCLC secondary underlie physiological problem , include follow medical conditions* : Baseline force expiratory volume ( FEV ) _1 &lt; 40 % predict Postoperative predict FEV_1 &lt; 30 % predict Severely reduce diffusion capacity Baseline hypoxemia and/or hypercapnia Exercise oxygen consumption &lt; 50 % predict Severe pulmonary hypertension Diabetes mellitus severe end organ damage Severe cerebral , cardiac , peripheral vascular disease Severe chronic heart disease NOTE : *Patients refuse PCR due preference , ideology , emotional psychological issue , mental illness , inability give inform consent eligible No evidence regional distant metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular See Disease Characteristics No active pericardial infection Pulmonary See Disease Characteristics No active pulmonary infection Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active systemic infection No concurrent illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic therapy No concurrent vaccine therapy Chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior lung mediastinal radiotherapy No concurrent standard fractionate radiotherapy No concurrent intensity modulate radiotherapy No concurrent cobalt60 charge particle beam ( include electron , proton , heavy ion ) Surgery See Disease Characteristics No concurrent surgery Other No concurrent antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>